Avasimibe
Avasimibe (PD-148515) is an orally active ACAT inhibitor (IC50: 3.3 μM) that reduces arterial cholesterol deposition. It also inhibits CYP2C9, 1A2, and 2C19 isoenzymes. This compound is used in research on atherosclerosis and drug metabolism, with applications in both in vitro enzymatic assays and in vivo models of hyperlipidemia.
Product Specifications
CAS Number
166518-60-1
Product Name Alternative
SOAT, mono- acylglycerol acyltransferase, Inhibitor, inhibit, PD148515, PD-148515, PD 148515, orally, Avasimibe, active, Acyltransferase, acyl-CoA:cholesterol acyltransferase, ACAT1, ACAT, ACAT2, CYP1A2, CYP2C19, CYP2C9, Diglyceride acyltransferase, Diacylglycerol acyltransferase, CI 1011, CI-1011, CI1011
Field of Research
Metabolism Research
Purity
>98%
Bioactivity
ACAT inhibitor
Form
Powder
Solubility
Ethanol:2 mg/mL (3.99 mM) ;10% DMSO+90% Corn Oil:5 mg/mL (9.97 mM) ; DMSO:102 mg/mL (203.3 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble)
Smiles
CC (C) c1cc (C (C) C) c (CC (=O) NS (=O) (=O) Oc2c (cccc2C (C) C) C (C) C) c (c1) C (C) C
Molecular Formula
C29H43NO4S
Molecular Weight
501.72
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
039162-ML490 100 µL
NSE4A, NT (NSMCE4A, C10orf86, Non-structural maintenance of chromosomes element 4 homolog A) (MaxLight 490) discontinued
Sign In for Pricing
View Details GTR15340455 1 Vial
Lentiviral human BFSP1 shRNA (UAS) - Lentiviral human BFSP1 shRNA (UAS, RFP) (100)
Sign In for Pricing
View Details